A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies.

Holida M, Linhart A, Pisani A, Longo N, Eyskens F, Goker-Alpan O, Wallace E, Deegan P, Tøndel C, Feldt-Rasmussen U, Hughes D, Sakov A, Rocco R, Almon EB, Alon S, Chertkoff R, Warnock DG, Waldek S, Wilcox WR, Bernat JA

Open source

DOI: 10.1002/jimd.12795
Published: 2025 Jan
Container: Journal of inherited metabolic disease
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/jimd.12795,
  title = {A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies.},
  author = {Holida M and Linhart A and Pisani A and Longo N and Eyskens F and Goker-Alpan O and Wallace E and Deegan P and Tøndel C and Feldt-Rasmussen U and Hughes D and Sakov A and Rocco R and Almon EB and Alon S and Chertkoff R and Warnock DG and Waldek S and Wilcox WR and Bernat JA},
  year = {2025},
  journal = {Journal of inherited metabolic disease},
  doi = {10.1002/jimd.12795},
  url = {https://doi.org/10.1002/jimd.12795}
}

RIS

TY  - JOUR
TI  - A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies.
AU  - Holida M
AU  - Linhart A
AU  - Pisani A
AU  - Longo N
AU  - Eyskens F
AU  - Goker-Alpan O
AU  - Wallace E
AU  - Deegan P
AU  - Tøndel C
AU  - Feldt-Rasmussen U
AU  - Hughes D
AU  - Sakov A
AU  - Rocco R
AU  - Almon EB
AU  - Alon S
AU  - Chertkoff R
AU  - Warnock DG
AU  - Waldek S
AU  - Wilcox WR
AU  - Bernat JA
PY  - 2025
JO  - Journal of inherited metabolic disease
DO  - 10.1002/jimd.12795
UR  - https://doi.org/10.1002/jimd.12795
ER  -

APA

M, H., A, L., A, P., N, L., F, E., O, G., E, W., P, D., C, T., U, F., D, H., A, S., R, R., EB, A., S, A., R, C., DG, W., S, W., WR, W., & JA, B. (2025). A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies.. Journal of inherited metabolic disease. https://doi.org/10.1002/jimd.12795

Source records

pubmed · retrieved 2026-09-26T00:25:07.502Z
europe-pmc · retrieved 2026-09-26T00:25:07.519Z